After PCI for ACS or stable CAD, DAPT for 1 mo vs. >1 mo reduces major bleeding without increasing stent thrombosis

Area of Science:

• Cardiology
• Clinical Trials
• Pharmacology

Background:

• Dual antiplatelet therapy (DAPT) is crucial after percutaneous coronary intervention (PCI).
• Optimal DAPT duration remains debated, balancing ischemic event prevention against bleeding risk.
• Current guidelines suggest varying durations, necessitating further evidence synthesis.

Purpose of the Study:

• To compare major bleeding and stent thrombosis rates between one-month DAPT and longer-term DAPT.
• To evaluate the safety and efficacy of abbreviated DAPT regimens.
• To inform clinical decision-making regarding DAPT duration post-PCI.

Main Methods:

• Systematic review and meta-analysis of randomized clinical trials (RCTs).
• Inclusion of studies comparing one-month DAPT with longer DAPT durations.
• Assessment of major bleeding and stent thrombosis as primary outcomes.

Main Results:

• One-month DAPT significantly reduced major bleeding compared to longer-term DAPT.
• No significant increase in stent thrombosis was observed with one-month DAPT.
• The findings suggest a favorable safety profile for shorter DAPT duration.

Conclusions:

• One-month DAPT is a viable strategy for reducing bleeding complications post-PCI.
• Shorter DAPT duration can be considered without compromising safety regarding stent thrombosis.
• This meta-analysis provides evidence supporting de-escalation of DAPT duration.